{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"160.900","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2025","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"301,666,673","primaryexch":"HKEX","ric":"2617.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BTML3Y8","am":"210.42","iv":"","ew_strike":"","as":"144.100","geographic_focus":null,"incorpin":"PRC","etp_baseCur":null,"ew_amt_os":"","bd":"143.100","registrar":"Tricor Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-26 10:38:37.0","lo52":"20.200","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Frank Wu","underlying_ric":"2617.HK","hi52":"679.500","issuer_name":"TransThera Sciences (Nanjing), Inc. - B - H Shares","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"143.000","mkt_cap":"43.19","f_aum_hkd":null,"ew_sub_per_to":"","ls":"143.200","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-16.600","aum":"","issued_shares_class_B":null,"vo":"1.41","secondary_listing_flag":false,"listing_date":"23 Jun 2025","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"TransThera Sciences (Nanjing), Inc. - B - H Shares","nm_s":"TRANSTHERA-B","sym":"2617","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.100","strike_price":"","summary":"TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.","op":"160.900","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"3/F, Bldg 9, Accelerator Ph 2<br/>Biotech &Pharmaceutical Valley<br/>Jiangbei New Area, Nanjing<br/>Jiangsu Province, PRC","pc":"-10.39","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"159.800","isin":"CNE100006T02","moneyness":""}},"qid":"1758890073354"}
